AstraZeneca (AZ) has announced that new real-world data from Canada shows its COVID-19 vaccine – Vaxzevria – was found to be highly effective after one dose against severe disease or hospitalisation caused by the Beta and Delta variants.

The pre-print results, from the Canadian Immunization Research Network (CIRN) with support from Public Health Agency of Canada and the Canadian Institutes of Health, showed one dose of Vaxzevria was 82% effective against hospitalisation or death caused by the Beta and Gamma COVID-19 variants.

On top of that, AZ’s jab showed high efficacy against the Delta and Alpha variants, showing an 87% reduction and 90% reduction of hospitalisations or deaths respectively.

One dose of Vaxzevria had lower efficacy against milder symptomatic disease than against severe disease, although AZ added that the indicated two dose schedule of the vaccine is known to enhance efficacy in this disease setting.

The vaccine’s effectiveness against any symptomatic disease was 50% for the Beta or Gamma variants, and 70% and 72% against the Delta and Alpha variants respectively.

The analysis included 69,533 individuals who tested positive for COVID-19 from December 2020 to May 2021 in Ontario, Canada, with 28,705 testing positive for non-variants of concern and 40,828 testing positive for a variant of concern.

“With different variants threatening to disrupt our route out of the pandemic, this real-world evidence shows that Vaxzevria, along with other vaccines used in Canada, provides a high level of protection against the most serious forms of the disease, even after just one shot,” Said Mene Pangalos, executive vice president, BioPharmaceuticals R&D at AZ.

“It is essential that we continue to protect as many people as possible in all corners of the world in order to get ahead of this deadly virus,” he added.

Reference
https://www.pharmatimes.com/news/az_says_its_covid-19_vaccine_protects_against_severe_disease_caused_by_variants_1373488

More News
Energy Crisis: The EU Chemical Industry Is Reaching Breaking Point
News · 11/11/2022

The current energy crisis has reached an unsustainable level for the European chemical industry. For the first time ever, the EU imports more chemicals than it exports, both in volume and value, resulting in a trade deficit of € 5.6 bn for the first half of 2022.

READ MORE
European Union proposes to add two new hazard classes to EU CLP regulation for endocrine disruptors (EDCs)
News · 17/10/2022

Endocrine Disrupting Chemicals (also referred to as hormone disruptors or EDCs) are synthetic chemicals that are not produced by the human body and that disrupt the normal functioning of humans and animals.

READ MORE
The Shipping Industry in a downward spiral
News · 03/10/2022

The shipping industry is now returning to normality and is in a downward spiral. The cost of shipping goods from China has slumped to the lowest level in more than two years as the world economy stumbles, dimming prospects for container carriers that turned in record profits during the pandemic.

READ MORE
Global Freight Situation
News · 08/09/2022

No precipitous plunge in container shipping rates, just ‘orderly’ decline.

READ MORE
3 Key Insights into the Global Food and Beverage Market
News · 02/08/2022

The global food and beverage market size is expected to grow from $5.8 trillion in 2021 to $6.4 trillion in 2022 at a growth rate of 9.7%. The food and beverage market size is expected to grow to $8.9 trillion in 2026 at a compound annual growth rate of 8.7%.

READ MORE
NEW DRUGS (AMENDMENT) RULES,2022 MANDATES QR CODES FOR ACTIVE PHARMACEUTICAL INGREDIENTS
News · 01/07/2022

The amendment makes QR codes mandatory on every active pharmaceutical ingredient. The Amendment Rules will come into force from January 01, 2023.

READ MORE
European Green Deal
News · 01/07/2022

On June 22, 2022, the Commission adopted pioneering proposals to restore damaged ecosystems and bring nature back across Europe, from agricultural land and seas, to forests and urban environments. The Commission also proposes to reduce the use and risk of chemical pesticides by 50% by 2030.

READ MORE
Neoadjuvant Dostarlimab is a promising treatment option in locally advanced dMMR rectal cancer
News · 01/07/2022

According to New York Times, in a small clinical trial, 18 patients took a drug called Dostarlimab for around six months, and in the end, every one of them saw their tumours disappear.

READ MORE
Global recession? Not yet…
News · 02/06/2022

As the war in Ukraine and pandemic disruptions continue to wreak havoc on supply chains, stagflation is here to stay – marked by low growth and high inflation for at least the next 12 months.

The pandemic as well as the war in Ukraine have stifled supply of commodities and goods and upended efficient distribution through global supply chains, forcing up prices of everyday goods such as fuel and food.

READ MORE